<DOC>
	<DOCNO>NCT02546427</DOCNO>
	<brief_summary>This phase I feasibility study evaluate feasibility hypofractionated whole pelvis radiotherapy 35 patient biopsy-proven intermediate- high-risk prostate cancer define NCCN risk criterion . Patients &gt; 15 % risk lymph node involvement define Roach equation 2/3 ( PSA ) +10 ( Gleason Score-6 ) . Day 0 study define time first LHRH/agonist/antagonist injection hormone therapy . Radiation therapy begin within 8 week ( +/- 1 week ) date first LHRH agonist/antagonist injection . Patients follow 6 week every 3 month first 24 month completion radiotherapy similar schedule usual standard care . A history physical , PSA , testosterone EPIC-26 questionnaire collect visit . Any toxicity accord CTCAE v. 4.0 criterion document . An interim analysis evaluate acute toxicity ( ≤90 day ) perform first follow-up visit the20th patient enrol protocol . The trial terminate &gt; 30 % acute grade 2 &gt; 5 % grade 3 great toxicity observe result radiation treatment CTCAE v. 4.0 criterion . Grade 2 toxicity define minimal , local noninvasive intervention . Grade 3 toxicity define severe medically significant immediately life-threatening event require hospitalization prolongation hospitalization . Previous study demonstrate approximately 30 % 5 % incidence Grade 2 Grade 3 great toxicity , respectively , conventionally fractionate radiotherapy follow brachytherapy .</brief_summary>
	<brief_title>Hypofractionated Whole Pelvic Radiotherapy Prostate</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically confirm intermediate highrisk prostate adenocarcinoma ( T1cT3b , PSA &gt; 10 , and/or Gleason score ≥ 7 ) great 15 % risk lymph node involvement determine Roach equation . History/physical examination digital rectal examination prostate within 8 week prior registration Zubrod performance status 02 Age ≥18 year Ability understand write informed consent document , willingness sign Prior concurrent invasive malignancy ( except nonmelanomatous skin cancer ) lymphomatous/hematogenous malignancy unless continually disease free minimum 5 year . Evidence distant metastasis Regional lymph node involvement Previous radical surgery ( prostatectomy ) cryosurgery prostate cancer Previous pelvic irradiation , prostate brachytherapy Previous concurrent cytotoxic chemotherapy prostate cancer Patients history inflammatory bowel disease major bowel surgery . Prior transurethral resection prostate ( TURP ) procedure .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>